¼¼°èÀÇ CRISPR ±â¹Ý À¯ÀüÀÚ ÆíÁý ½ÃÀå
CRISPR-based Gene Editing
»óǰÄÚµå : 1791599
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 172 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,242,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,727,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ CRISPR ±â¹Ý À¯ÀüÀÚ ÆíÁý ½ÃÀåÀº 2030³â±îÁö 110¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 44¾ï ´Þ·¯·Î ÃßÁ¤µÈ CRISPR ±â¹Ý À¯ÀüÀÚ ÆíÁý ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 110¾ï ´Þ·¯¿¡ À̸£°í, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 16.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ CRISPR ŰƮ ¹× ½Ã¾àÀº CAGR18.3%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 77¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. CRISPR ¶óÀ̺귯¸® ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ CAGR 12.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 12¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 15.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ CRISPR ±â¹Ý À¯ÀüÀÚ ÆíÁý ½ÃÀåÀº 2024³â¿¡ 12¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 17¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 15.3%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 15.3%¿Í 13.9%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 11.7%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ CRISPR À¯ÀüÀÚ ÆíÁý ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

CRISPR À¯ÀüÀÚ ÆíÁýÀÌ »ý¸í°øÇÐÀ» º¯È­½ÃŰ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî? Á¤¹ÐÀÇ·áÀÇ È¹±âÀûÀÎ ¹ßÀüÀ» ޱ¸ÇÏ´Ù

¼¼°è CRISPRÀ» ÅëÇÑ À¯ÀüÀÚ ÆíÁý ½ÃÀåÀº À¯Àü°øÇÐÀÇ ¹ßÀü, »ý¸í°øÇÐ ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø Áõ°¡, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. CRISPR(Clustered Regularly Interspaced Short Palindromic Repeats) ±â¼úÀº À¯ÀüÀÚ ÆíÁý ºÐ¾ß¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ ³ôÀº Á¤È®µµ¿Í È¿À²ÀûÀÎ À¯ÀüÀÚ º¯ÇüÀ» °¡´ÉÇÏ°Ô Çß½À´Ï´Ù. °â»ó ÀûÇ÷±¸ ºóÇ÷, ±ÙÀÌ¿µ¾çÁõ, ³¶Æ÷¼º ¼¶À¯Áõ°ú °°Àº À¯Àü¼º ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ À¯ÀüÀÚ Ä¡·á ¿ëµµÀÇ ±Þ°ÝÇÑ Áõ°¡´Â ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, CRISPRÀº ¾Ï ¸é¿ªÄ¡·á¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, Á¾¾çÀ» º¸´Ù È¿°úÀûÀ¸·Î Ç¥ÀûÀ¸·Î »ïÀ» ¼ö ÀÖµµ·Ï ¸é¿ª¼¼Æ÷¸¦ º¯Çü½Ãų ¼ö ÀÖ½À´Ï´Ù. ÇÕ¼º»ý¹°Çп¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ CRISPRÀº À¯ÀüÀÚ º¯Çü ÀÛ¹°, ¹ÙÀÌ¿À¿¬·á »ý»êÀ» À§ÇÑ ¹Ì»ý¹° °øÇÐ, ³»º´¼º °¡Ãà °³¹ß¿¡µµ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀ» ¼±µµÇÏ´Â CRISPR ±â¹Ý ¿ëµµ´Â? ÁÖ¿ä ºÎ¹®º° ºÐ¼®

½ÃÀå ¼¼ºÐÈ­´Â Ä¡·á¿ë, ³ó¾÷¿ë, »ê¾÷¿ëÀ¸·Î ±¸ºÐµË´Ï´Ù. À¯ÀüÁúȯÀÇ ¿øÀÎÀÎ À¯ÀüÀÚ º¯À̸¦ ±³Á¤Çϱâ À§ÇØ CRISPRÀÇ È°¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó À¯ÀüÀÚ Ä¡·á¿Í Àç»ýÀÇÇÐÀ» Æ÷ÇÔÇÑ Ä¡·á ºÐ¾ß°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. CRISPRÀº ÀÛ¹° ¼öÈ®·® Çâ»ó, ³»º´¼º ½Ä¹° °³¹ß, ½Ä·® ¾Èº¸ °³¼±¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. »ê¾÷ »ý¸í°øÇÐ ºÐ¾ßµµ CRISPRÀÇ ÇýÅÃÀ» ¹Þ°í ÀÖÀ¸¸ç, È¿¼Ò »ý»ê, ¹ÙÀÌ¿À¿¬·á ÇÕ¼º, ÇÕ¼º »ý¹°ÇÐ Çõ½Å¿¡ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. ¼È·Ï(SHERLOCK)À̳ª µðÅØÅÍ(DETECTR)¿Í °°Àº CRISPR ±â¹Ý Áø´Ü¾àÀÇ ÃâÇöÀº ½Å¼ÓÇÏ°í ºñ¿ë È¿À²ÀûÀÎ Áúº´ °ËÃâÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ½ÃÀåÀÇ ¹üÀ§¸¦ ´õ¿í È®ÀåÇϰí ÀÖ½À´Ï´Ù.

AI, ³ª³ë±â¼ú, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½ºÀÇ ¿ªÇÒ, CRISPRÀ» ÅëÇÑ À¯ÀüÀÚ ÆíÁýÀ» ÁÖµµÇÏ´Â Çõ½ÅÀº ¾î¶»°Ô ÀÌ·ç¾îÁö°í Àִ°¡?

CRISPR »ê¾÷Àº ÀΰøÁö´É(AI), ³ª³ë±â¼ú, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º(Bioinformatics)ÀÇ ÅëÇÕÀ¸·Î ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. AI À¯ÀüÀÚ ÆíÁý ¾Ë°í¸®ÁòÀº Á¤È®µµ¸¦ ³ôÀ̰í, ¿ÀÇÁ Ÿ°Ù È¿°úÀÇ À§ÇèÀ» ÁÙÀ̸ç, ÆíÁý È¿À²À» Çâ»ó½Ãŵ´Ï´Ù. Cas12, Cas13 µî Â÷¼¼´ë Cas È¿¼ÒÀÇ °³¹ß·Î CRISPRÀÇ ´É·ÂÀº DNA ÆíÁý¿¡ ±×Ä¡Áö ¾Ê°í RNA º¯Çü±îÁö È®´ëµÇ¾ú½À´Ï´Ù. ÁöÁú ³ª³ëÀÔÀÚ ¹× ¹ÙÀÌ·¯½º º¤Å͸¦ Æ÷ÇÔÇÑ ³ª³ë±â¼ú ±â¹ÝÀÇ CRISPR Àü´Þ ½Ã½ºÅÛÀº À¯ÀüÀÚ ÆíÁý Ä¡·áÀÇ È¿À²¼º°ú ¾ÈÀü¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ý¹°Á¤º¸ÇÐ µµ±¸ÀÇ ¹ßÀüÀ¸·Î ¿¬±¸ÀÚµéÀº CRISPR »óÈ£ ÀÛ¿ëÀ» º¸´Ù Á¤È®ÇÏ°Ô ¸ðµ¨¸µÇϰí À¯ÀüÀÚ ÆíÁý ¿öÅ©Ç÷ο츦 ÃÖÀûÈ­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. DNA ¿°±â¼­¿­À» ¹Ù²ÙÁö ¾Ê°í À¯ÀüÀÚ ¹ßÇöÀ» ±³Á¤ÇÏ´Â CRISPR ±â¹Ý ÈļºÀ¯ÀüÇÐÀû ÆíÁýÀÇ µîÀåÀº º¹ÀâÇÑ Áúº´ Ä¡·á¿¡ »õ·Î¿î °¡´É¼ºÀ» Á¦½ÃÇϰí ÀÖ½À´Ï´Ù.

CRISPR À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ ¼ºÀåÀ» À̲ô´Â ¿äÀÎÀº ¹«¾ùÀΰ¡? ÁÖ¿ä ½ÃÀå ¿µÇâ¿äÀο¡ ´ëÇÑ ¼³¸í

CRISPRÀ» ÅëÇÑ À¯ÀüÀÚ ÆíÁý ½ÃÀåÀÇ ¼ºÀåÀº »ý¸í°øÇÐ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, Áúº´ Ä¡·á¿¡ ´ëÇÑ ÀÀ¿ë È®´ë, Àü´Þ ¸ÞÄ¿´ÏÁòÀÇ ¹ßÀü¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç¿Í »ý¸í°øÇÐ ±â¾÷µéÀÇ À¯ÀüÀÚ Ä¡·á ÇÁ·Î±×·¥ È®´ë´Â ½ÃÀåÀÇ »ó¾÷Àû ÀáÀç·ÂÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ÆíÁý ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø°ú ±ÔÁ¦ Áö¿øµµ ±â¼ú Çõ½ÅÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. CRISPRÀ» Ȱ¿ëÇØ ȯÀÚ ¸ÂÃãÇü Ä¡·á¹ýÀ» °³¹ßÇÏ´Â ¸ÂÃãÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀå¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª Àΰ£ »ý½Ä¼¼Æ÷ °èÅë ÆíÁý¿¡ ´ëÇÑ À±¸®Àû ¿ì·Á¿Í ±ÔÁ¦Àû Á¶»ç´Â ¿©ÀüÈ÷ Áß¿äÇÑ °úÁ¦ÀÔ´Ï´Ù. Áö¼ÓÀûÀÎ °úÇÐÀÇ ¹ßÀü°ú À¯ÀüÀÚ ÆíÁý ¿ëµµÀÇ ±¤¹üÀ§ÇÑ ¼ö¿ëÀ¸·Î CRISPR ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È Çõ½ÅÀûÀÎ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

Á¦Ç°(CRISPR ŰƮ ¹× ½Ã¾à, CRISPR ¶óÀ̺귯¸®), ¿ëµµ(»ý¹°ÀÇÇÐ ¿ëµµ, ³ó¾÷ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ÃÖÁ¾ ¿ëµµ, Çмú±â°ü ¹× ¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ, °è¾à ¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå°ú °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global CRISPR-based Gene Editing Market to Reach US$11.0 Billion by 2030

The global market for CRISPR-based Gene Editing estimated at US$4.4 Billion in the year 2024, is expected to reach US$11.0 Billion by 2030, growing at a CAGR of 16.3% over the analysis period 2024-2030. CRISPR Kits & Reagents, one of the segments analyzed in the report, is expected to record a 18.3% CAGR and reach US$7.7 Billion by the end of the analysis period. Growth in the CRISPR Libraries segment is estimated at 12.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 15.3% CAGR

The CRISPR-based Gene Editing market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 15.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.3% and 13.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.7% CAGR.

Global CRISPR-Based Gene Editing Market - Key Trends & Drivers Summarized

Why Is CRISPR-Based Gene Editing Transforming Biotechnology? Exploring the Breakthroughs in Precision Medicine

The global CRISPR-based gene editing market has witnessed rapid expansion, driven by advancements in genetic engineering, increased funding for biotechnology research, and the growing demand for precision medicine. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized the field of gene editing, enabling highly precise and efficient genetic modifications. The surge in gene therapy applications, aimed at treating genetic disorders such as sickle cell anemia, muscular dystrophy, and cystic fibrosis, has been a key driver of market growth. Additionally, CRISPR is playing an instrumental role in cancer immunotherapy, enabling the modification of immune cells to target tumors more effectively. With increasing interest in synthetic biology, CRISPR is also being utilized in the development of genetically engineered crops, microbial engineering for biofuel production, and disease-resistant livestock.

Which CRISPR-Based Applications Are Leading the Market? A Breakdown of Key Segments

The CRISPR-based gene editing market is segmented into therapeutic, agricultural, and industrial applications. The therapeutic segment, which includes gene therapy and regenerative medicine, dominates the market, as CRISPR is increasingly used to correct genetic mutations responsible for inherited diseases. Agricultural applications are also witnessing significant growth, with CRISPR being used to enhance crop yield, develop disease-resistant plants, and improve food security. The industrial biotechnology sector has also benefited from CRISPR, with applications in enzyme production, biofuel synthesis, and synthetic biology innovations. The emergence of CRISPR-based diagnostics, such as SHERLOCK and DETECTR, has further expanded the market’s scope by enabling rapid and cost-effective disease detection.

How Is Innovation Driving CRISPR-Based Gene Editing? The Role of AI, Nanotechnology & Bioinformatics

The CRISPR industry is evolving with the integration of artificial intelligence (AI), nanotechnology, and bioinformatics. AI-driven gene editing algorithms have enhanced precision, reducing the risk of off-target effects and improving editing efficiency. The development of next-generation Cas enzymes, such as Cas12 and Cas13, has expanded CRISPR’s capabilities beyond DNA editing to include RNA modifications. Nanotechnology-based CRISPR delivery systems, including lipid nanoparticles and viral vectors, are improving the efficiency and safety of gene-editing therapies. Additionally, advancements in bioinformatics tools are enabling researchers to model CRISPR interactions more accurately, optimizing gene-editing workflows. The rise of CRISPR-based epigenetic editing, which modifies gene expression without altering DNA sequences, has opened new possibilities for treating complex diseases.

What’s Driving the Growth of the CRISPR-Based Gene Editing Market? Key Market Influencers Explained

The growth in the CRISPR-based gene editing market is fueled by rising investment in biotechnology research, increasing applications in disease treatment, and advancements in delivery mechanisms. The expansion of gene therapy programs by pharmaceutical and biotech companies has strengthened the market’s commercial potential. Government funding initiatives and regulatory support for genome editing research have also accelerated innovation. The growing demand for personalized medicine, which leverages CRISPR to develop patient-specific treatments, has further boosted market growth. However, ethical concerns and regulatory scrutiny regarding human germline editing remain key challenges. With ongoing scientific advancements and broader acceptance of gene-editing applications, the CRISPR market is expected to witness transformative growth in the coming years.

SCOPE OF STUDY:

The report analyzes the CRISPR-based Gene Editing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Products (CRISPR Kits & Reagents, CRISPR Libraries); Application (Biomedical Applications, Agricultural Applications); End-Use (Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use, Contract Research Organizations End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â